Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide

British Journal of Cancer

Volumn 75, Issue 5, 1997, Pages 715-721

  Toffoli, G ^a   Sorio, R ^a   Gigante, M ^a   Corona, G ^a   Galligioni, E ^a   Boiocchi, M ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cyclosporin A; Multidrug resistance; Renal cell carcinoma; Teniposide

Indexed keywords

BILIRUBIN; CYCLOSPORIN A; GLYCOPROTEIN P; TENIPOSIDE;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NEUTROPENIA; NEUTROPHIL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING;

EID: 0031041852     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.127     Document Type: Article

References (34)

1. Boiocchi M and Toffoli G (1992) Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance. Eur J Cancer 28A: 1099 1105
2. Charuk JH, Wong PY and Reithmeier RA (1995) Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A. Am J Physiol 269: F31 F39
3. Chaudhary PM and Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94
4. Clark PI and Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12: 223-252
5. Evans WK, Sinkule JA and Crom WR (1982) Pharmacokinetics of temposide (VM26) and etoposide (VP26-213) in children with cancer. Cancer Chem Pharmacol 7: 147 150
6. Fojo AT, Ueda K, Slamon DJ, Poplack DG. Gottesman MM and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265 269
7. Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155 199
8. Fridborg H, Jonsson B, Nygren P, Csoka K, Nilsson K, Oberg G. Kristensen J. Bergh J, Tholander B, Olsen L, Jakobson A and Larsson R (1994) Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. Br J Cancer 70: 11-17
9. Gosland MP, Brophy NA, Duran GE. Yahanda AM, Adler KM, Hardy RI, Halsey J and Sikic BI (1991) Bilirubin: a physiological substrate for the multidrug transporter. Proc Annu Meet Am Assoc Cancer Res 32: A2533
10. Kimura K, Saijo M, UI M and Enomoto T (1994) Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA lopoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem 269: 1173 1176
11. Klimecki WT, Futscher BW, Grogan TM and Dalton WS (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83: 2451-2458
12. Lehnert M (1993) Reversal of P-glycoprotein-associated multidrug resistance: the challenge continues. Eur J Cancer 29A: 636 638
13. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP and Sikic BI (1992) Alteration of etoposide pharmacokineties and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635 1642
14. Maurer G and Lemaire M (1986) Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 18: 25-34
15. Meador J, Sweet P, Stupecky M, Wetzel M, Murray S, Gupta S and Slater L (1987) Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res 47: 6216-6219
16. Osieka R, Seeber S, Pannenbacker R, Soll D, Glatte P and Schmidt CG (1986) Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol 18: 198 202
17. Raderer M and Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72: 3553 3563
18. Relling MV, Neniec J, Schuetz EG, Schuetz ID, Gopzalez EJ and Korzekwa ER (1994) O-demethlation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45: 352-358
19. Rodenburg CJ, Nooter K. Herweijer H, Seynaeve C. Oosterom R, Stoter G and Verweij J (1991) Phase II study of combining vinblastine and eyelosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2: 305-306
20. Schuurhuis GJ. Broxterman HJ, Cervantes A, Van Heijningen TH DE Lange JH, Baak JP, Pinedo HM and Lankelma J (1989) Quantitative determination of factors contributing to doxorubein resistance in multidrug-resistant cells. J Natl Cancer Inst 81: 1987-1892
21. Skovsgaard T (1978) Mechanism of cross-resistance between vincristine and daunorubiein in Ehrlich ascutes tumor cells. Cancer Res 38: 4722-4727
22. Sonneveld P and Nooter K (1990) Reversal of drug-resistance by cyclosporin-A in a patient with acute myclocytic leukaemia. Br J Haematol 75: 208 211
23. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B and Nooter K (1992) Modulation of multidurg-resistant multiple myeloma by cyclosporin. The I eukaemia Group of the EORTC and the HOVON. Lancet 340: 255 259
24. Taylor RJ (1990) Introduzione all analisi degli errori. pp. 202-203. Zanichelli. Bologna
25. Tew KD, Houghton PJ and Houghton JA (1993) Proclinical and Clinical Modulation of Anticancer Drugs. pp. 126. CRC Press: Boca Raton
26. Toffoli G, Simone F, Corona G, Raschack M, Cappelletto B, Gigante M and Boiocchi M (1995) Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem Pharmacol 50: 1245-1255
27. Toffoli G, Corona G, Gigante M and Boiocchi M (1996) Inhibition of P gD-activity and cell cycle dependent chemotheraphy to govorubicin to. multidrug-resistant LoVo human colon cancer cell line Eur J Cancer 32A: 1591-1597
28. Twentyman PR (1992) Cyclosporins as drug resistance modificts. Biochem Pharmacol 43: 109-117
29. Verweij J. Herweijer H, Oosterom R, Van Der Burg ME, Planting AS, Seynaeve C, Stoter G and Nooter K (1991) A phase II study of epidoxonthicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance Br J Cancer 64: 361-364
30. Vincent PC (1983) Kinetics of lekemia and control of cell divisim and replicationM in Leukemia Gunz FW and Hendersor FS (eds) pp 77 718 Grune & Stratton: New York
31. Warner E, Tobe SW, Andrulis II. Pei Y, Trachtenberg J and Skorecki KL (1995) Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell. carcinoma. Am J Clin Oncol 18: 251-256
32. Wilson WH, Jamis Dow C, Bryant G, Balis FM, Klecker RW, Baies ST, Chahnan BA, Steinberg SM, Kobler DR and Wittes RE (1995) Phase land pharmacokinetic study of the multidrug resistance modulator dewerapamil with EPOCH chemotherapy. J Clin Oncol 13: 1985-1994
33. Yagoda A. Abi Rached B and Petrylak D (1995) Chemothraphy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 22: 42-60
34. Yahanda AM. Adler KM. Fisher GA, Brophy NA, Halsey J. Hardy RI. Gosland. MP. Lum BL and Sikie BI (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624-1634